Literature DB >> 26759404

Etanercept-induced myositis: do we have to stop it? A surprising outcome.

Hassan Tariq1, Bibi Ayesha1, Karen Weidenheim2, Giovanni Franchin1.   

Abstract

We discuss a case of a 47-year-old man who presented with progressive proximal muscle weakness of the upper and lower extremities and unstable gait. He had been on etanercept for 6 months for severe psoriasis and psoriatic arthritis with good control of his disease. Serum creatine kinase (CK) level was found to be 5666 U/L and muscle biopsy showed a marked inflammatory myopathic process likely secondary to etanercept. He was started on high-dose steroids and advised to discontinue etanercept. Despite our recommendation, he never stopped using etanercept due to fear of a psoriasis flare. Three months later, he had significant improvement of clinical symptoms, normalised serum CK levels and discontinued prednisone. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26759404      PMCID: PMC4716375          DOI: 10.1136/bcr-2015-213577

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.

Authors:  David M Pariser; Craig L Leonardi; Kenneth Gordon; Alice B Gottlieb; Stephen Tyring; Kim A Papp; Joanne Li; Scott W Baumgartner
Journal:  J Am Acad Dermatol       Date:  2011-10-19       Impact factor: 11.527

2.  Tumor necrosis factor inhibitor-associated dermatomyositis.

Authors:  Rachel Klein; Misha Rosenbach; Ellen J Kim; Brian Kim; Victoria P Werth; Jonathan Dunham
Journal:  Arch Dermatol       Date:  2010-07

3.  Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.

Authors:  Yuki Ishikawa; Naoichiro Yukawa; Koichiro Ohmura; Yuji Hosono; Yoshitaka Imura; Daisuke Kawabata; Takaki Nojima; Takao Fujii; Takashi Usui; Tsuneyo Mimori
Journal:  Clin Rheumatol       Date:  2010-02-09       Impact factor: 2.980

4.  Interferon-gamma inhibits proliferation, differentiation, and creatine kinase activity of cultured human muscle cells. II. A possible role in myositis.

Authors:  A E Kalovidouris; Z Plotkin; D Graesser
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

Review 5.  Bacterial, fungal, parasitic, and viral myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.

Authors:  Stephanie W Liu; Nicole F Velez; Christina Lam; Alisa Femia; Scott R Granter; Henry B Townsend; Ruth Ann Vleugels
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

Review 7.  The spectrum of statin myopathy.

Authors:  Payam Mohassel; Andrew L Mammen
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

8.  Association between statin-associated myopathy and skeletal muscle damage.

Authors:  Markus G Mohaupt; Richard H Karas; Eduard B Babiychuk; Verónica Sanchez-Freire; Katia Monastyrskaya; Lakshmanan Iyer; Hans Hoppeler; Fabio Breil; Annette Draeger
Journal:  CMAJ       Date:  2009-07-07       Impact factor: 8.262

9.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

Review 10.  Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis.

Authors:  Dario Kivelevitch; Bobbak Mansouri; Alan Menter
Journal:  Biologics       Date:  2014-04-17
View more
  1 in total

Review 1.  Arthritis in Idiopathic Inflammatory Myopathies.

Authors:  Martin Klein; Heřman Mann; Jiří Vencovský
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.